Abstract: The present invention relates to an ultra-high molecular weight polyethylene and a process for preparing the same, said ultra-high molecular weight polyethylene has a viscosity-average molecular weight of 150-1000×104 g/mol, a metal element content of 0-50 ppm, a bulk density of 0.30-0.55 g/cm3, a true density of 0.900-0.940 g/cm3, a melting point of 140-152° C., and a crystallinity of 40-75%, and said polyethylene satisfies at least one of condition (1) and condition (2): Condition (1): tensile elasticity modulus is greater than 250 MPa, preferably greater than 280 MPa, more preferably greater than 300 MPa, Condition (2): Young's modulus is greater than 300 MPa, preferably greater than 350 MPa. The ultra-high molecular weight polyethylene has high mechanical properties, high melting point, low metal element content and ash content, and the preparation process is simple, flexible and adjustable, and the ultra-high molecular weight ethylene copolymer has a high tensile elasticity module.

Abstract: Disclosed herein is a method of electroreduction with a working electrode and counter electrode. The method includes a step of electrocatalyzing carbon monoxide and/or carbon dioxide in the presence of one or more nucleophilic co-reactants in contact with a catalytically active material present on the working electrode, thereby forming one or more carbon-containing products electrocatalytically.

Abstract: The present invention relates to an ethylene polymer and a process for preparing the same, wherein the ethylene polymer has an average particle size of 50-3000 ?m, a bulk density of 0.28-0.55 g/cm3, a true density of 0.930-0.980 g/cm3, a melt index at a load of 2.16 Kg at 190° C. of 0.01-2500 g/10 min, a crystallinity of 30-90%, a melting point of 105-147° C., a comonomer molar insertion rate of 0.01-5 mol %, a weight-average molecular weight of 2×104 g/mol-40×104 g/mol, and a molecular weight distribution of 1.8-10. In the preparation process, raw materials containing ethylene, hydrogen gas and a comonomer are subjected to a tank-type slurry polymerization with an alkane solvent having a boiling point of 5-55° C. or a mixed alkane solvent having a saturated vapor pressure of 20-150 KPa at 20° C. as the polymerization solvent in the presence of a polyethylene catalytic system, at the molar ratio of hydrogen gas to ethylene of 0.01-20:1, preferably 0.

Abstract: The invention is related to a class of hydrophilic poly(meth)acrylamide-based copolymers each comprising dangling (i.e., pendant) reactive chains each terminated with a carboxyl group groups and at least 50% by mole of (meth)acrylamide repeating units relative to all repeating units of the hydrophilic poly(meth)acrylamide-based copolymer. The hydrophilic copolymers have a relatively high affinity to a base coating of a polyanionic polymer on a medical device or contact lens and are highly reactive towards azetidinium groups of an azetidinium-containing polymer upon heating. They can find particular use in producing water-soluble highly-branched hydrophilic polymeric material and in producing water gradient contact lenses.

Abstract: Introduced here are computer programs and computer-implemented techniques for discovering malicious emails and then remediating the threat posed by those malicious emails in an automated manner. A threat detection platform may monitor a mailbox to which employees of an enterprise are able to forward emails deemed to be suspicious for analysis. This mailbox may be referred to as an “abuse mailbox” or “phishing mailbox.” The threat detection platform can examine emails contained in the abuse mailbox and then determine whether any of those emails represent threats to the security of the enterprise. For example, the threat detection platform may classify each email contained in the abuse mailbox as being malicious or non-malicious. Thereafter, the threat detection platform may determine what remediation actions, if any, are appropriate for addressing the threat posed by those emails determined to be malicious.

Abstract: The present invention relates to a process for continuously producing an ultra-high molecular weight polyethylene by the ethylene slurry polymerization, wherein raw materials containing ethylene and optionally at least one comonomer are subjected to a continuous slurry polymerization in a hydrogen free atmosphere in the ethylene slurry polymerization condition by using 2-6 ethylene slurry polymerization reaction tanks connected in series, and the deviations of the polymerization temperatures, the polymerization pressures, and the gas phase compositions between the tanks each other are controlled to certain ranges. The ultra-high molecular weight polyethylene having the viscosity-average molecular weight of 150-800×104 g/mol can be continuously produced. This process has flexible polymerization manner, large room for adjusting and controlling, and stable polymer performance.

Abstract: The invention provides a hydrophilized polydiorganosiloxane vinylic crosslinker which comprises (1) a polydiorganosiloxane polymer chain comprising dimethylsiloxane units and hydrophilized siloxane units each having one methyl substituent and one monovalent C4-C40 organic radical substituent having two to six hydroxyl groups, wherein the molar ratio of the hydrophilized siloxane units to the dimethylsiloxane units is from about 0.035 to about 0.15, and (2) two terminal (meth)acryloyl groups. The hydrophilized polydiorganosiloxane vinylic crosslinker has a number average molecular weight of from about 3000 Daltons to about 80,000 Daltons. The present invention is also related to a silicone hydrogel contact lens, which comprises repeating units derived from a hydrophilized polydiorganosiloxane vinylic crosslinker of the invention.

Abstract: The present invention generally relates to inherently wettable silicone hydrogel contact lenses having relatively high oxygen permeability, relatively high equilibrium water content and relatively low elastic modulus. The present invention is also related to a method for making such inherently wettable silicone hydrogel contact lenses.

Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.

Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.

Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.

Abstract: The present disclosure provides methods of treating breast cancer including administering aqueous suspensions com-prising solubilized fulvestrant, non-solubilized fulvestrant particles having one or more of an LD Dv(1 0) between about 1.5 and about 2.1 microns, an LD Dv(50) between about 5.5 and about 9.0 microns, and an LD Dv(90) between about 15 and about 35 microns, with the aqueous suspensions further including a surfactant, a polyvinylpyrrolidone, and a sugar alcohol, and a water-soluble excipient. The water-soluble excipient can be an aryl-Ci-6alk-OH, a Ci-6alkyl-OH, a buffering salt, a polysorbate, a polyalkylene glycol, a Ci-i2alkylene glycol, a phosphatidylcholine, or a combination thereof.

Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.

Abstract: A method for producing embedded hydrogel contact lenses comprises at least the following steps: obtaining an insert made of a crosslinked polymeric material comprising repeating units of a free-radical photoinitiator; placing the insert in a female lens mold half; dosing an amount of a lens-forming composition to immerse the insert in the female lens mold half; closing tightly a male lens mold half onto the top of the female lens mold half halves to form a molding assembly; actinically curing both the lens-forming composition in the molding assembly to form an embedded hydrogel lens precursor which comprises a bulk hydrogel material formed the lens-forming composition and the insert that is embedded therein and covalently linked to the bulk hydrogel material.

Abstract: The invention provides a method for making silicone hydrogel contact lenses in a relatively efficient and consistent manner from a lens formulation (i.e., a polymerizable composition) including a thermal initiator having a 10-hour half-life temperature (T10h?) under a controlled thermal curing scheme. A method of the invention comprises a step of curing the lens formulation in an oven according to a thermal curing profile that comprises or consists essentially of increasing the oven's temperature from room temperature or a temperature that is at least about 5° C. lower than T10h? to a temperature that is at least 30° C. higher than T10h? at a selected rate (e.g., from about 1° C./minute to about 10° C./minute). Under such a controlled thermal curing scheme, the lens diameter of the fully-hydrated silicone hydrogel contact lenses obtained according to a method of the invention does not vary significantly with the positions of the molds in the oven.

Abstract: The present invention generally relates to inherently wettable silicone hydrogel contact lenses having relatively high oxygen permeability, relatively high equilibrium water content and relatively low elastic modulus. The present invention is also related to a method for making such inherently wettable silicone hydrogel contact lenses.

Abstract: A method for producing embedded hydrogel contact lenses comprises at least the following steps: obtaining an insert made of a crosslinked polymeric material comprising iniferter moieties covalently attached thereto; placing the insert in a female lens mold half; dosing an amount of a lens-forming composition to immerse the insert in the female lens mold half; closing tightly a male lens mold half onto the top of the female lens mold half halves to form a molding assembly; curing the lens-forming composition in the molding assembly to form an embedded hydrogel lens precursor which comprises a bulk hydrogel material formed the lens-forming composition and the insert that is embedded therein and covalently linked to the bulk hydrogel material.

Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.

Abstract: The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof. Pharmaceutical compositions comprising fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, and methods of treating diseases or disorders, including migraine are also disclosed.

Abstract: The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof. Pharmaceutical compositions comprising fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, and methods of treating diseases or disorders, including migraine are also disclosed.